Trade Edwards Lifesciences - EW CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.27
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022179 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02218%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000043 %(-$0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022179 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000043 %
  (-$0.01)

Key Stats

• Prev. Close: 83.9
• Open: 84.45
• 1-Year Change: 11.54%
• Day's Range: 83.18 - 85.09

Trade Edwards Lifesciences - EW

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Edwards Lifesciences Corp revenues increased 19% to $5.23B. Net income increased 83% to $1.5B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 20% to $3.42B, Surgical Heart Valve Therapy segment increase of 17% to $889.1M, Critical Care segment increase of 15% to $834.9M, United States segment increase of 18% to $2.96B, Europe segment increase of 26% to $1.19B.

Equity composition

Common Stock $1 Par, 12/10, 350M auth., 117,100,000 issd. less 2,000 shs. in Treas. @ $102M. Insiders control 0.64%. 4/3/00,Company spun off from Baxter International. 05/10, 2-for-1 stock split. 12/15, 2-for-1 stock split.